Supplemental material
Journal of Medical Economics
Volume 25, 2022 - Issue 1
Oncology
Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States
, 
, , , , , , , & show all
Mohammad A. Chaudharyb Bristol Myers Squibb, Princeton, NJ, USAhttps://orcid.org/0000-0001-6552-9093
https://orcid.org/0000-0001-6552-9093, , , , Eleonora Testaa Parexel International, Stockholm, SwedenCorrespondence[email protected]
https://orcid.org/0000-0002-9878-7299
https://orcid.org/0000-0002-9878-7299, Johan Klinta Parexel International, Stockholm, Swedenhttps://orcid.org/0000-0001-7023-7685
https://orcid.org/0000-0001-7023-7685, Adam Leec Bristol Myers Squibb, Uxbridge, UKhttps://orcid.org/0000-0001-8834-1296
https://orcid.org/0000-0001-8834-1296, Solomon J. Lubingab Bristol Myers Squibb, Princeton, NJ, USAhttps://orcid.org/0000-0003-0539-9156
https://orcid.org/0000-0003-0539-9156 & show all